DDInter463 DDInter1676
An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564). Dacarbazine with Oblimersen is in clinical trials for the treatment of malignant melanoma.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Dacarbazine {u} (Compound) treats {v} (Disease) skin cancer
Dacarbazine {u} (Compound) binds {v} (Gene) POLA2
Dacarbazine {u} (Compound) upregulates {v} (Gene) CADM1
Dacarbazine {u} (Compound) is included by {v} (Pharmacologic Class) Alkylating Activity
Dacarbazine {u} (Compound) downregulates {v} (Gene) HMGCS1
Dacarbazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lomefloxacin
Dacarbazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cinoxacin
Dacarbazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Floxuridine
Dacarbazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brentuximab vedotin
Dacarbazine {u} may lead to a major life threatening interaction when taken with {v} Aldesleukin
Dacarbazine (Compound) treats skin cancer (Disease)
Dacarbazine (Compound) binds POLA2 (Gene)
Dacarbazine (Compound) upregulates CADM1 (Gene)
Dacarbazine (Compound) is included by Alkylating Activity (Pharmacologic Class)
Dacarbazine (Compound) downregulates HMGCS1 (Gene)
Dacarbazine may cause a minor interaction that can limit clinical effects when taken with Lomefloxacin
Dacarbazine may cause a minor interaction that can limit clinical effects when taken with Cinoxacin
Dacarbazine may cause a moderate interaction that could exacerbate diseases when taken with Floxuridine
Dacarbazine may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Dacarbazine may lead to a major life threatening interaction when taken with Aldesleukin